{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:44:12Z","timestamp":1789688652280,"version":"4.0.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012155","name":"Channel 7 Telethon Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012155","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"publisher","award":["MRCG 2016-03"],"award-info":[{"award-number":["MRCG 2016-03"]}],"id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001108","name":"The Ophthalmic Research Institute of Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001801","name":"University of Western Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001801","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fighting Blindness (Ireland), Healy Medical Research Foundation, Vyluma"},{"name":"Perron Foundation Health Research Gratn"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To investigate interactions between iris colour and low-concentration atropine on outcomes relevant to clinical myopia management<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A post-hoc, exploratory meta-analysis of three randomised clinical trials investigating atropine 0.01% or 0.05% eye drops vs placebo: the Western Australian Atropine Treatment of Myopia study, the Myopia Treatment Study and the Myopia Outcome Study of Atropine in Children. Iris colour was graded as brown or not brown (including blue\/green\/hazel). Change in accommodative amplitude, pupil diameter, spherical equivalent refraction (SER) and axial length were assessed using linear mixed models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In participants (baseline ages 5\u201316 years) using atropine 0.01% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009396), pupil diameter change did not differ by iris colour (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009\u2265\u20090.15), while accommodative amplitude decreased more in not brown vs brown iris colour groups at month 12 (adjusted difference\u2009=\u2009\u22121.07D, 95% CI: \u22122.02, \u22120.12,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03), but not at month 24 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.76). Change in pupil and accommodative outcomes with 0.05% atropine (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200966) did not differ by iris colour (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009\u2265\u20090.10). Among not brown iris colour participants, myopia progression was lower in the atropine 0.01% vs placebo group at 24 months (SER: +0.17D, 95% CI: 0.07, 0.26,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001; axial length: \u22120.09\u2009mm, 95% CI: \u22120.12, \u22120.05,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), but not among brown iris colour participants (SER: \u22120.08D, 95% CI: \u22120.20, 0.05; axial length: +0.03\u2009mm, 95% CI: \u22120.02, 0.07).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Change in pupil diameter and accommodative amplitude with low-concentration atropine largely did not differ between iris colour groups. Among participants using 0.01% atropine eye drops, there was less 24-month myopia progression compared to placebo in participants with blue\/green\u00a0irides, but not with brown irides.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-026-04478-1","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T08:13:08Z","timestamp":1777277588000},"page":"1499-1506","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Low-concentration atropine for management of myopia progression: does iris colour matter?"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8957-0733","authenticated-orcid":false,"given":"Gareth","family":"Lingham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Loughman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6635-1098","authenticated-orcid":false,"given":"Samantha SY","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael X.","family":"Repka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8474-8856","authenticated-orcid":false,"given":"Eoin","family":"Kerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"G\u00f3mez S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Kobia-Acquah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest Kyei","family":"Nkansah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7004-6026","authenticated-orcid":false,"given":"Ian","family":"Flitcroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Mackey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"4478_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-42108-y","volume":"13","author":"MA Bullimore","year":"2023","unstructured":"Bullimore MA, Brennan NA. The underestimated role of myopia in uncorrectable visual impairment in the United States. Sci Rep. 2023;13:15283.","journal-title":"Sci Rep"},{"key":"4478_CR2","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1001\/jamaophthalmol.2016.4009","volume":"134","author":"JWL Tideman","year":"2016","unstructured":"Tideman JWL, Snabel MCC, Tedja MS, Van Rijn GA, Wong KT, Kuijpers RAM, et al. Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia. JAMA Ophthalmol. 2016;134:1355\u201363.","journal-title":"JAMA Ophthalmol"},{"key":"4478_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1167\/iovs.61.4.49","volume":"61","author":"AEG Haarman","year":"2020","unstructured":"Haarman AEG, Enthoven CA, Willem Tideman JL, Tedja M, Verhoeven VJM, Klaver CW. The complications of myopia: a review and meta-analysis. Invest Ophthalmol Vis Sci. 2020;61:49.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4478_CR4","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","volume":"123","author":"BA Holden","year":"2016","unstructured":"Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123:1036\u201342.","journal-title":"Ophthalmology"},{"key":"4478_CR5","doi-asserted-by":"publisher","first-page":"e82763","DOI":"10.1371\/journal.pone.0082763","volume":"8","author":"JF Wu","year":"2013","unstructured":"Wu JF, Bi HS, Wang SM, Hu YY, Wu H, Sun W, et al. Refractive error, visual acuity and causes of vision loss in children in Shandong, China. The Shandong Children Eye Study. PLoS One. 2013;8:e82763.","journal-title":"PLoS One"},{"key":"4478_CR6","doi-asserted-by":"publisher","first-page":"7504","DOI":"10.1167\/iovs.11-8343","volume":"53","author":"J Sun","year":"2012","unstructured":"Sun J, Zhou J, Zhao P, Lian J, Zhu H, Zhou Y, et al. High prevalence of myopia and high myopia in 5060 Chinese University students in Shanghai. Invest Ophthalmol Vis Sci. 2012;53:7504\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4478_CR7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ajo.2018.09.011","volume":"197","author":"J Zhao","year":"2019","unstructured":"Zhao J, Xu X, Ellwein LB, Guan H, He M, Liu P, et al. Causes of visual impairment and blindness in the 2006 and 2014 nine-province surveys in rural China. Am J Ophthalmol. 2019;197:80\u20137.","journal-title":"Am J Ophthalmol"},{"key":"4478_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100923","volume":"83","author":"NA Brennan","year":"2020","unstructured":"Brennan NA, Toubouti YM, Cheng X, Bullimore MA. Efficacy in myopia control. Prog Retin Eye Res. 2020;83:100923.","journal-title":"Prog Retin Eye Res"},{"key":"4478_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","volume":"119","author":"A Chia","year":"2012","unstructured":"Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology. 2012;119:347\u201354.","journal-title":"Ophthalmology"},{"key":"4478_CR10","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","volume":"113","author":"WH Chua","year":"2006","unstructured":"Chua WH, Balakrishnan V, Chan YH, Tong L, Ling Y, Quah BL, et al. Atropine for the treatment of childhood myopia. Ophthalmology. 2006;113:2285\u201391.","journal-title":"Ophthalmology"},{"key":"4478_CR11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","volume":"123","author":"A Chia","year":"2016","unstructured":"Chia A, Lu Q-S, Tan D. Five-year clinical trial on Atropine for the Treatment Of Myopia 2: myopia control with atropine 0.01% eyedrops. Ophthalmology. 2016;123:391\u20139.","journal-title":"Ophthalmology"},{"key":"4478_CR12","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ophtha.2021.10.002","volume":"129","author":"JC Yam","year":"2022","unstructured":"Yam JC, Zhang XJ, Zhang Y, Wang YM, Tang SM, Li FF, et al. Three-year clinical trial of Low-concentration Atropine for Myopia Progression (LAMP) study: continued versus washout: phase 3 report. Ophthalmology. 2022;129:308\u201321.","journal-title":"Ophthalmology"},{"key":"4478_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","volume":"126","author":"JC Yam","year":"2019","unstructured":"Yam JC, Jiang Y, Tang SM, Law AKPP, Chan JJ, Wong E, et al. Low-concentration atropine for myopia progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmology. 2019;126:113\u201324.","journal-title":"Ophthalmology"},{"key":"4478_CR14","first-page":"e245","volume":"102","author":"J Loughman","year":"2023","unstructured":"Loughman J, Kobia-Acquah E, Lingham G, Butler J, Loskutova E, Mackey DA, et al. Myopia outcome study of atropine in children: two-year result of daily 0.01% atropine in a European population. Acta Ophthalmol. 2023;102:e245\u201356.","journal-title":"Acta Ophthalmol"},{"key":"4478_CR15","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/ceo.14148","volume":"50","author":"SS-Y Lee","year":"2022","unstructured":"Lee SS-Y, Lingham G, Blaszkowska M, Sanfilippo PG, Koay A, Franchina M, et al. Low-concentration atropine eyedrops for myopia control in a multi-racial cohort of Australian children: a randomised clinical trial. Clin Exp Ophthalmol. 2022;50:1001\u201312.","journal-title":"Clin Exp Ophthalmol"},{"key":"4478_CR16","doi-asserted-by":"crossref","unstructured":"Zadnik K, Schulman E, Flitcroft I, Fogt JS, Blumenfeld LC, Fong TM, et al. Efficacy and safety of 0.01% and 0.02% atropine for the treatment of pediatric myopia progression over 3 years: a randomized clinical trial. JAMA Ophthalmol. 2023;141:990\u20139.","DOI":"10.1001\/jamaophthalmol.2023.2097"},{"key":"4478_CR17","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1001\/jamaophthalmol.2023.2855","volume":"141","author":"MX Repka","year":"2023","unstructured":"Repka MX, Weise KK, Chandler DL, Wu R, Melia BM, Manny RE, et al. Low-dose 0.01% atropine eye drops vs placebo for myopia control: a randomized clinical trial. JAMA Ophthalmol. 2023;141:756\u201365.","journal-title":"JAMA Ophthalmol"},{"key":"4478_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0022-3565(25)30482-9","volume":"197","author":"M Salazar","year":"1976","unstructured":"Salazar M, Shimada K, Patil PN. Iris pigmentation and atropine mydriasis. J Pharmacol Exp Ther. 1976;197:79\u201388.","journal-title":"J Pharmacol Exp Ther"},{"key":"4478_CR19","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1089\/jop.1999.15.257","volume":"15","author":"EJ German","year":"1999","unstructured":"German EJ, Wood D, Hurst MA. Ocular effects of antimuscarinic compounds: is clinical effect determined by binding affinity for muscarinic receptors or melanin pigment? J Ocul Pharmacol Ther. 1999;15:257\u201369.","journal-title":"J Ocul Pharmacol Ther"},{"key":"4478_CR20","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1097\/00006324-198610000-00001","volume":"63","author":"JV Lovasik","year":"1986","unstructured":"Lovasik JV. Pharmacokinetics of topically applied cyclopentolate HCI and tropicamide. Optom Vis Sci. 1986;63:787\u2013803.","journal-title":"Optom Vis Sci"},{"key":"4478_CR21","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/j.1442-9071.2010.02487.x","volume":"39","author":"DA Mackey","year":"2011","unstructured":"Mackey DA, Wilkinson CH, Kearns LS, Hewitt AW. Classification of iris colour: review and refinement of a classification schema. Clin Exp Ophthalmol. 2011;39:462\u201371.","journal-title":"Clin Exp Ophthalmol"},{"key":"4478_CR22","doi-asserted-by":"crossref","unstructured":"Loughman J, Lingham G, Nkansah EK, Kobia-Acquah E, Flitcroft DI. Efficacy and safety of different atropine regimens for the treatment of myopia in children. JAMA Ophthalmol. 2025;143:134\u201344.","DOI":"10.1001\/jamaophthalmol.2024.5703"},{"key":"4478_CR23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/0014-4835(80)90047-0","volume":"30","author":"B Atlasik","year":"1980","unstructured":"Atlasik B, Stepien K, Wilczok T. Interaction of drugs with ocular melanin in vitro. Exp Eye Res. 1980;30:325\u201331.","journal-title":"Exp Eye Res"},{"key":"4478_CR24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/ICL.0000000000000677","volume":"46","author":"A Upadhyay","year":"2020","unstructured":"Upadhyay A, Beuerman RW. Biological mechanisms of atropine control of myopia. Eye Contact Lens. 2020;46:129\u201335.","journal-title":"Eye Contact Lens"},{"key":"4478_CR25","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/OPX.0000000000002044","volume":"100","author":"P Kumar","year":"2023","unstructured":"Kumar P, Saxena R, Dhiman R, Phuljhele S, Kumar V, Chawla R, et al. Evaluation of the levels of low-dose topical atropine (0.01%) in aqueous and vitreous humor in human eyes. Optom Vis Sci. 2023;100:530\u20136.","journal-title":"Optom Vis Sci"},{"key":"4478_CR26","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1111\/aos.15235","volume":"101","author":"S Wei","year":"2023","unstructured":"Wei S, Li SM, An W, Du J, Liang X, Sun Y, et al. Myopia progression after cessation of low-dose atropine eyedrops treatment: A two-year randomized, double-masked, placebo-controlled, cross-over trial. Acta Ophthalmol. 2023;101:e177\u201384.","journal-title":"Acta Ophthalmol"},{"key":"4478_CR27","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10384-021-00822-y","volume":"65","author":"O Hieda","year":"2021","unstructured":"Hieda O, Hiraoka T, Fujikado T, Ishiko S, Hasebe S, Torii H, et al. Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study. Jpn J Ophthalmol. 2021;65:315\u201325.","journal-title":"Jpn J Ophthalmol"},{"key":"4478_CR28","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.ophtha.2021.01.026","volume":"128","author":"R Saxena","year":"2021","unstructured":"Saxena R, Dhiman R, Gupta V, Kumar P, Matalia J, Roy L, et al. Atropine for the treatment of childhood myopia in India: multicentric randomized trial. Ophthalmology. 2021;128:1367\u20139.","journal-title":"Ophthalmology"},{"key":"4478_CR29","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/aos.16604","volume":"102","author":"R Iribarren","year":"2024","unstructured":"Iribarren R, Cunha C, Kaymak H, Grzybowski A. Preservatives and pH in low-dose atropine formulations for clinical trials. Acta Ophthalmol. 2024;102:364\u20136.","journal-title":"Acta Ophthalmol"},{"key":"4478_CR30","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3390\/jcm10040588","volume":"10","author":"H Austermann","year":"2021","unstructured":"Austermann H, Schaeffel F, Mathis U, Hund V, Mu\u00dfhoff F, Ziemssen F, et al. Corneal penetration of low-dose atropine eye drops. J Clin Med. 2021;10:588.","journal-title":"J Clin Med"},{"key":"4478_CR31","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1001\/jamaophthalmol.2020.3820","volume":"138","author":"S Wei","year":"2020","unstructured":"Wei S, Li SM, An W, Du J, Liang X, Sun Y, et al. Safety and efficacy of low-dose atropine eyedrops for the treatment of myopia progression in Chinese children a randomized clinical trial. JAMA Ophthalmol. 2020;138:1178\u201384.","journal-title":"JAMA Ophthalmol"},{"key":"4478_CR32","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/08164622.2022.2033603","volume":"106","author":"B Cyphers","year":"2023","unstructured":"Cyphers B, Huang J, Walline JJ. Symptoms and ocular findings associated with administration of 0.01% atropine in young adults. Clin Exp Optom. 2023;106:311\u201321.","journal-title":"Clin Exp Optom"},{"key":"4478_CR33","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1007\/s00417-018-4112-8","volume":"256","author":"H Kaymak","year":"2018","unstructured":"Kaymak H, Fricke A, Mauritz Y, L\u00f6winger A, Klabe K, Breyer D, et al. Short-term effects of low-concentration atropine eye drops on pupil size and accommodation in young adult subjects. Graefes Arch Clin Exp Ophthalmol. 2018;256:2211\u20137.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4478_CR34","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s10792-021-01755-8","volume":"41","author":"L Joachimsen","year":"2021","unstructured":"Joachimsen L, Farassat N, Bleul T, B\u00f6hringer D, Lagr\u00e8ze WA, Reich M. Side effects of topical atropine 0.05% compared to 0.01% for myopia control in German school children: a pilot study. Int Ophthalmol. 2021;41:2001\u20138.","journal-title":"Int Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04478-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04478-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04478-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T14:21:32Z","timestamp":1783434092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04478-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4478"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04478-1","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"1 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GL is an employee of, and JL and IF are founding directors of Ocumetra, a company with interest in clinical tools to assist myopia management.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The MOSAIC, WA-ATOM, and MTS1 studies all adhered to the tenets of the Declaration of Helsinki, were approved by respective Human Research Ethics Committees [\n                      \n                      ,\n                      \n                      ,\n                      \n                      ] and were prospectively registered with clinical trial databases (EudraCT2016-003340-37, ACTRN12617000598381 and NCT03334253). Parents or caregivers provided written informed consent in all cases and participants provided verbal (WA-ATOM) or, where able, written (MOSAIC, MTS1) assent prior to commencing in each study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and informed consent"}}]}}